ASX - By Stock
|
PAA |
Re:
Ann: Proposed issue of securities - PAA
|
|
qwert0
|
15 |
3.0K |
8 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
15
|
3.0K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
qwert0
|
159 |
38K |
15 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
38K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
qwert0
|
159 |
38K |
25 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
38K
|
25
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
qwert0
|
159 |
38K |
15 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
38K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
qwert0
|
159 |
38K |
11 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
38K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
qwert0
|
159 |
38K |
8 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
38K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
qwert0
|
61 |
12K |
18 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
61
|
12K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
qwert0
|
206 |
53K |
28 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
206
|
53K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
qwert0
|
206 |
53K |
32 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
206
|
53K
|
32
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
qwert0
|
206 |
53K |
20 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
206
|
53K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
qwert0
|
655 |
162K |
3 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
655
|
162K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
qwert0
|
655 |
162K |
10 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
655
|
162K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
qwert0
|
655 |
162K |
21 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
655
|
162K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
qwert0
|
85 |
21K |
21 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
21K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
qwert0
|
655 |
162K |
13 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
655
|
162K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
qwert0
|
655 |
162K |
38 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
655
|
162K
|
38
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
qwert0
|
58 |
16K |
11 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
58
|
16K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
qwert0
|
86 |
21K |
11 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
21K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust receives Orphan Drug Designation for monepantel
|
|
qwert0
|
43 |
12K |
18 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
43
|
12K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust receives Orphan Drug Designation for monepantel
|
|
qwert0
|
43 |
12K |
29 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
43
|
12K
|
29
|
|
ASX - By Stock
|
EM2 |
Re:
EM2
|
|
qwert0
|
181 |
63K |
5 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
181
|
63K
|
5
|
|
ASX - By Stock
|
CYM |
Re:
Ann: Investor Presentation
|
|
qwert0
|
124 |
34K |
7 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
124
|
34K
|
7
|
|
ASX - By Stock
|
CYM |
Re:
Ann: Investor Presentation
|
|
qwert0
|
124 |
34K |
11 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
124
|
34K
|
11
|
|
ASX - By Stock
|
CYM |
Re:
Ann: Investor Presentation
|
|
qwert0
|
124 |
34K |
16 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
124
|
34K
|
16
|
|
ASX - By Stock
|
CYM |
Re:
Ann: Investor Presentation
|
|
qwert0
|
124 |
34K |
11 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
124
|
34K
|
11
|
|
ASX - By Stock
|
CYM |
Re:
Ann: Investor Presentation
|
|
qwert0
|
124 |
34K |
8 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
124
|
34K
|
8
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Mineral Resource Estimate Increased to 28Mt @ 1.35% Copper
|
|
qwert0
|
77 |
33K |
3 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
77
|
33K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
qwert0
|
1.4K |
365K |
16 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
1.4K
|
365K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
qwert0
|
1.4K |
365K |
24 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
1.4K
|
365K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
qwert0
|
83 |
24K |
10 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
83
|
24K
|
10
|
|
ASX - By Stock
|
EM2 |
Re:
EM2
|
|
qwert0
|
181 |
63K |
5 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
181
|
63K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
qwert0
|
250 |
64K |
29 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
250
|
64K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
qwert0
|
250 |
64K |
19 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
250
|
64K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
qwert0
|
83 |
24K |
8 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
83
|
24K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
qwert0
|
83 |
24K |
14 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
83
|
24K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
qwert0
|
261 |
73K |
17 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
73K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
qwert0
|
261 |
73K |
38 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
73K
|
38
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
qwert0
|
77 |
20K |
11 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
77
|
20K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
qwert0
|
77 |
20K |
10 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
77
|
20K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
qwert0
|
77 |
20K |
28 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
20K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
qwert0
|
77 |
20K |
41 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
20K
|
41
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
qwert0
|
77 |
20K |
17 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
20K
|
17
|
|
ASX - By Stock
|
EM2 |
Re:
EM2
|
|
qwert0
|
181 |
63K |
3 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
181
|
63K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
NZT gone but hasn't forgotten
|
|
qwert0
|
66 |
19K |
21 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
66
|
19K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
NZT gone but hasn't forgotten
|
|
qwert0
|
66 |
19K |
21 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
66
|
19K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
qwert0
|
1.4K |
365K |
21 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
1.4K
|
365K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
qwert0
|
1.4K |
365K |
18 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
1.4K
|
365K
|
18
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Entitlement Offer Closes Raising $4.18 million
|
|
qwert0
|
37 |
11K |
5 |
24/03/24 |
24/03/24 |
ASX - By Stock
|
37
|
11K
|
5
|
|
ASX - By Stock
|
EM2 |
Re:
Letter to share holders
|
|
qwert0
|
20 |
9.4K |
5 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
20
|
9.4K
|
5
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Entitlement Offer Closes Raising $4.18 million
|
|
qwert0
|
37 |
11K |
7 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
37
|
11K
|
7
|
|